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In this issue ofCell StemCell, Daquinag et al. (2011) take a lesson from the oncology field to search for stromal
progenitor cells within adipose tissue. Their use of phage display biopanning in vivo identified an isoform of
the extracellular matrix protein decorin as a receptor for the adipokine resistin.In the current issue of Cell Stem Cell, Da-
quinag et al. (2011) present a tour-de-
force technical approach that uses phage
display methods to characterize adipose
tissue-specific progenitor cells in vivo.
While phage display has been used
extensively in the cancer field to charac-
terize high-affinity peptides recognizing
tumor cells, its application in the
stromal/stem cell arena has been limited
(Brown, 2010). Dr. Mikhail Kolonin, the
senior author on this UT-Houston team
effort, had prior expertise in the applica-
tion of phage display methods to cancer
biology and adipose tissue (referenced
in Daquinag et al., 2011). Using high-
throughput screening of a combinatorial
library, he had identified high-affinity
peptides recognizing surface proteins on
a panel of tumor cell lines. Additionally,
Kolonin and his colleagues had extended
this approach in vivo, using it to identify
organ selective peptides in the pancreas
and to target adipose tissue for ablation.
Building on this foundation, the authors
here combined murine tissue-specific
phage screening in vivo with flow cytome-
try to target novel surface markers on
adipose progenitor cells (Daquinag et al.,
2011). By focusing on CD34+CD31
CD45 stromal cells in adipose tissue
and lung in sequential screens, they iden-
tified a peptide (WAT7) enriched in
adipose tissue relative to lung by a 15-
fold ratio (Daquinag et al., 2011). Confocal
microscopy was used to pinpoint the co-
localization of the fluorochrome-labeled
WAT7 peptide to cells positive for the
pericytic markers CD146 and alpha-
smooth muscle actin (Daquinag et al.,
2011). Using affinity chromatography and
protein sequencing methods, the ligandfor the WAT7 peptide was identified as
the nonglyconated isoform of decorin, a
secreted extracellularmatrix protein asso-
ciated with obesity and diabetes (Bolton
et al., 2008). Taking it a step further, the
authors raised antibodies against WAT7
to identify the corresponding endogenous
peptide (Daquinag et al., 2011). Surpris-
ingly, the anti-WAT7 antibodies recog-
nized resistin, an adipokine first identified
as a murine fat cell-secreted protein
implicated in insulin resistance (Schwartz
and Lazar, 2011). When the nonglyco-
nated decorin protein identified as the
WAT7 ligand was overexpressed in the
3T3-L1preadipocyte cell line, it stimulated
proliferation and cell migrationwhile inhib-
iting adipogenesis in a resistin-responsive
manner (Daquinag et al., 2011).
The development of monoclonal anti-
body reagents recognizing cell-specific
surface antigens revolutionized the hema-
topoietic stem cell (HSC) field. Using
selective panels of antibodies, it has
been possible to map the developmental
pathway for B- and T-lymphocyte line-
ages. Historically, the stromal/stem cell
field in bone marrow and adipose tissue
has continued to lag behind that of HSCs
due to the lack of cell-and tissue-specific
antibodies and surface markers. Multiple
groups, including that of Simmons and
Torok-Storb (1991), among others, devel-
oped monoclonal antibodies such as
Stro-1 against bone marrow stromal cell
lines, and these remain valuable and
widely used reagents. Nevertheless, there
remains a need for novel approaches to
identify and distinguish stromal/stem cells
across tissues and species. The in vivo
phage display technology presented by
Daquinag et al. offers a next-generation,Cell Stemfunctional approach to addressing this
unmet need.
Their current manuscript focuses
exclusively on the adipogenic potential
of adipose tissue-derived cells (Daquinag
et al., 2011). The work raises intriguing
questions whether this lineage-specific
cell population has direct links to multipo-
tent mesenchymal stromal/stem cells.
Mesenchymal stromal/stem cells were
originally isolated in bone marrow and
mesenchymal stem cells (MSCs) from
this tissue source have received the
greatest attention in the literature. More
recently, similar populations have since
been characterized in amnion, placenta,
skeletal muscle, tendon, and fat, as well
as other tissues. While these various
cell populations share many features in
common, they differ with respect to their
surface immunophenotype and differenti-
ation potential. In direct comparisons,
adipose-derived adipose stromal cells
(ASCs) exhibited superior adipogenesis,
while bone marrow-derived bone marrow
stem cells (BMSCs) showed greater
osteogenesis (Sakaguchi et al., 2005).
Recently, the concept of ASCs and
MSCs as ‘‘perivascular’’ or ‘‘pericytic’’
cells based on their expression of
CD146 and related markers has received
attention (Crisan et al., 2008; Zannettino
et al., 2008). Nevertheless, long-term
BrdU labeling studies have localized
putative progenitor cells not only to the
perivascular space but also to extravas-
cular sites adjacent to mature adipocytes
within adipose tissue (Staszkiewicz et al.,
2009). This background highlights the
need for novel biomarkers, such as the
decorin isoform described in the current
paper, as potential tools to distinguishCell 9, July 8, 2011 ª2011 Elsevier Inc. 1
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Previewsand enrich tissue-specific progenitors
which may prove to be MSC-like cells.
Such reagents have the potential to accel-
erate the pace for the translation of MSC-
like cells to the clinic, as well as to
advance our understanding of their basic
science at the mechanistic level. Addi-
tionally, phage display may yield peptides
suitable for targeted manipulation and/or
selective homing of MSC-like cells
in situ. Indeed, Kolonin and colleagues
have employed such approaches to
selectively ablate adipose tissue in vivo
(Kolonin et al., 2004).
While resistin has been studied for over
a decade, its receptor and signal trans-
duction mechanism remains an active
area of investigation (Schwartz and Lazar,
2011). Few studies have reported
evidence of a resistin receptor (Schwartz
and Lazar, 2011). The current work
provides novel evidence that resistin
interacts directly with decorin. It remains
to be seen if and how decorin mediates
resistin signal transduction in multiple
tissues. Of course, there are always
caveats. For example, there are species-
specific differences in the expression
and functionality of resistin (Schwartz
and Lazar, 2011). While resistin is associ-2 Cell Stem Cell 9, July 8, 2011 ª2011 Elseviatedwith adipocytes in themouse, human
macrophagesalso express this protein, so
the biology of the WAT7/decorin interac-
tion in the mouse may not mimic that in
man (Schwartz and Lazar, 2011). Still,
such minor points should not detract
from the bigger story, namely, that phage
display methods have emerged as an
unbiased in vivo discovery tool for the
characterization and identification of
novel surface markers and signal trans-
duction pathways for stem cells. This
method has the potential to shed new light
on our understanding of how stem cells in
solid organs interact with their microenvi-
ronmental niche in situ. The next challenge
will be for other stem cell laboratories to
reproduce and expand on the UT-Hous-
ton team’s exciting approach.
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The molecular mechanisms specifying hematopoietic stem cells (HSCs) in the vertebrate embryo remain
poorly understood. Recently in Nature, Traver and colleagues demonstrate that timed wnt to Notch relay
signaling across multiple cell types serves as an early upstream mechanism of HSC induction in zebrafish
(Clements et al., 2011).Every second of our life, millions of blood
cells have to be replaced to maintain
our blood system. All these cells are
ultimately produced from hematopoietic
stem cells (HSCs), which have the
capacity to give rise to all blood cell typesand to self-renew in order to maintain
HSC numbers life-long. Due to their fasci-
nating ability to repopulate the entire
blood system of a recipient organism
upon simple transplantation, HSCs have
successfully been used for regenerativecell therapy for decades. However, the
low number of clinically available HSCs
remains a major restriction for their appli-
cation. Novel approaches for their expan-
sion or de novo generation in vitro would
therefore have a huge clinical impact.
